Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06969326 · ClinicalTrials.gov registry record · Phase 3
Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy
A Phase 3 study of Gender Dysphoria and Hysterectomy, sponsored by Women and Infants Hospital of Rhode Island.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06969326: Recruiting Phase 3 study of Gender Dysphoria and Hysterectomy, sponsored by Women and Infants Hospital of Rhode Island.
NCT06969326 is a Phase 3 study of Gender Dysphoria and Hysterectomy that is actively recruiting participants, run by Women and Infants Hospital of Rhode Island. The registered enrollment target is 48 participants, below the 173-participant average among 8 other Gender Dysphoria trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06969326, a Phase 3 study of Gender Dysphoria and Hysterectomy, is actively recruiting participants, sponsored by Women and Infants Hospital of Rhode Island.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if applying a single dose of topical estrogen cream in the operating room at the end of your hysterectomy (removal of uterus and cervix) improves the postoperative experience with bleeding and potential symptoms of dysphoria (a feeling of discomfort or distress). Topical estrogen cream is sometimes used if patients have increased risk of bleeding with surgery but is not currently utilized in a consistent way. This study aims to answer the question of whether this is a helpful treatment and should be included in standard postoperative care.
Primary Outcome
The investigators hypothesize that administration of postoperative estrogen cream vaginally in the operating room will decrease the need for health system contact for bleeding in the initial postoperative period. Patients will be asked to complete a brief email survey on postoperative days: 1, 3, 7, \& 14 as well as at final postoperative visit \~42 days. This survey will target multiple things Outcome 1: Quantity of bleeding Determined by patient report: 1) small amount of spotting with wipin
Conditions Studied
Interventions
- OTHER No intervention
- DRUG Use of topical estradiol
Study Locations (1)
Rhode Island
- Women & Infants Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2026-12-01 |
| Phase | Phase 3 |
What NCT06969326 shows while recruiting
NCT06969326 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 173-participant average among 8 other Gender Dysphoria trials with a reported enrollment target (72% lower).
The record links to 3 conditions, with Gender Dysphoria appearing as the primary indexed condition, and to 2 interventions - of which No intervention is the first listed.
NCT06969326 reports a single indexed study location in Rhode Island.
Frequently Asked Questions
What is clinical trial NCT06969326 about?
NCT06969326 is a clinical study titled "Topical Estrogen: Brief Intervention to Improve Postoperative Experience for Transgender Men Undergoing Hysterectomy". The purpose of this study is to determine if applying a single dose of topical estrogen cream in the operating room at the end of your hysterectomy (removal of uterus and cervix) improves the postoperative experience with bleeding and potential symptoms of dysphoria (a feeling of discomfort or distr...
What is the current status of trial NCT06969326?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 48 participants. The study started on 2025-05-01. Estimated completion is 2026-12-01.
What conditions does trial NCT06969326 study?
This clinical trial studies the following conditions: Gender Dysphoria, Hysterectomy, Postoperative Bleeding.
What interventions are being tested in trial NCT06969326?
The interventions under investigation include: No intervention (OTHER), Use of topical estradiol (DRUG).
Who is sponsoring clinical trial NCT06969326?
This trial is sponsored by Women and Infants Hospital of Rhode Island, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06969326 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gender Dysphoria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06969326's enrollment target sits among peer trials
48 7th of 8 higher than 2 of 8 other Gender Dysphoria trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gender Dysphoria trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
RECRUITING · Phase 3
-
Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth
RECRUITING
-
Evaluating the Efficacy of Force Modulating Tissue Bridge Device in Preventing Hypertrophic Scars Following Gender-Affirming Mastectomy
RECRUITING · NA
-
Effect of Nitropaste in Chest Masculinizing Surgery
RECRUITING · Phase 4
-
Testicular Tissue Cryopreservation in the Setting of Gender-Affirming Therapy
ACTIVE NOT RECRUITING
-
Ovarian Tissue Cryopreservation in the Setting of Gender-affirming Therapy
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI